Add BrightSurf on Google Email

Movement matters: Light activity led to better survival in diabetes, heart, kidney disease

A new study found that light intensity activities, such as walking or household chores, were associated with a lower risk of death for people with CKM syndrome. The researchers used data from the National Health and Nutrition Examination Survey to compare activity level duration for each CKM syndrome stage.

SourceAmerican Heart Association·JournalJournal of the American Heart Association·DateJan 7, 2026

Early detection and targeted blood purification could prevent kidney failure in ICU patients, new review finds

Early recognition of cast nephropathy through novel biomarkers can guide timely treatment, while tailored extracorporeal therapies show promise in preventing irreversible kidney damage. The review emphasizes the need for standardized biomarker-guided pathways and multicenter trials to advance personalized kidney support.

SourceJournal of Intensive Medicine·JournalJournal of Intensive Medicine·TypeLiterature review·DateJan 6, 2026

‘Tubuloids’ offer a realistic platform for modeling chronic kidney disease

Researchers from Institute of Science Tokyo developed 'tubuloids' to capture the slow progression of chronic kidney disease (CKD), replicating key features such as DNA damage, cellular senescence, inflammation, and fibrosis. This realistic platform provides a new way to develop and test treatments for millions globally.

SourceInstitute of Science Tokyo·JournalAdvanced Healthcare Materials·TypeExperimental study·DateDec 16, 2025

Insilico Medicine and Taigen achieves license agreement to develop and commercialize AI-driven PHD inhibitor for anemia of Chronic Kidney Disease (CKD)

Insilico Medicine and Taigen Biotechnology collaborate to develop and commercialize ISM4808, an AI-driven PHD inhibitor for treating anemia of Chronic Kidney Disease (CKD). The partnership grants TaiGen exclusive rights for further development, commercialization, and sub-licensing in the Greater China area.

Older age, chronic kidney disease and cerebrovascular disease linked with increased risk for paralysis and death after West Nile virus infection

A study published in JAMA Network Open found that older adults with chronic kidney disease or cerebrovascular disease are at double the risk for developing neuroinvasive West Nile virus infection, which can lead to paralysis and death. The study identified several risk factors, including male sex, immune suppressants, and multiple scle...

SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA Network Open·TypeData/statistical analysis·DateDec 10, 2025

FAU Engineering study takes a ‘quantum leap’ to detect kidney disease

A recent FAU Engineering study leverages quantum computing to enhance the accuracy of chronic kidney disease (CKD) diagnosis. The research team developed and compared two automated systems: Classical Support Vector Machine (CSVM) and Quantum Support Vector Machine (QSVM). CSVM achieved remarkable 98.75% accuracy, while QSVM reached 87....

SourceFlorida Atlantic University·JournalInformatics and Health·TypeData/statistical analysis·DateNov 12, 2025

Disagreement between two kidney function tests predicts serious health problems

A new study reveals that a large gap between two common kidney function tests may indicate future disease, particularly among older adults. The research found that over a third of hospitalized participants had a significant difference in their creatinine and cystatin C readings, which can predict serious health problems.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalJAMA·TypeMeta-analysis·DateNov 7, 2025

Reducing reliance on corticosteroids with rituximab: renewed hope for adult-onset patients with relapsing nephrotic syndrome

A randomized clinical trial has shown that rituximab is effective in preventing relapses and reducing the need for corticosteroids in adults with relapsing nephrotic syndrome. The study involved 66 adult patients treated with either rituximab or a placebo, with impressive results at the 49-week follow-up.

SourceThe University of Osaka·JournalJAMA·TypeRandomized controlled/clinical trial·DateNov 5, 2025

Catching Alport syndrome through universal age-3 urine screening

Researchers found that over 30% of children referred for Alport syndrome testing at age 3 already required therapeutic intervention, highlighting the potential benefits of early detection. The study suggests introducing a urine testing system may enable intervention before kidney dysfunction onset.

SourceKobe University·JournalKidney International Reports·TypeData/statistical analysis·DateOct 7, 2025

Study links shift work to higher risk of kidney stones, influenced by lifestyle factors

A study published in Mayo Clinic Proceedings found that shift workers have a 15% higher risk of developing kidney stones, especially younger workers and those with low levels of manual labor. Lifestyle factors such as BMI, fluid intake, and smoking habits significantly contribute to the occurrence of kidney stones.

SourceElsevier·JournalMayo Clinic Proceedings·TypeData/statistical analysis·DateOct 1, 2025

Heat and toxic exposures could harm kidneys in agricultural workers

A new study by the University of Arizona found that heat exposure and toxic metal exposure can increase signs of kidney injury in agricultural workers. The study suggests that providing mandatory breaks, water, electrolyte replacement, and restrooms nearby can help prevent heat-related illnesses and kidney damage.

SourceUniversity of Arizona Health Sciences·JournalEnvironmental Research·TypeObservational study·DateSep 23, 2025

USC Stem Cell scientists unlock blueprint for lab-grown kidney cells with preclinical value

USC Stem Cell scientists have developed a blueprint for generating specific kidney cell types on demand, holding immense value for preclinical studies of new therapeutics and congenital kidney diseases. The team successfully created lab-grown proximal tubule cells that can absorb sugar and protein, respond to chemotherapy drugs, and pr...

SourceKeck School of Medicine of USC·JournalNature Communications·TypeExperimental study·DateSep 4, 2025

Metabolic insights from kidney ‘immune hubs’ point to new therapeutic concept

Researchers discovered that immune hubs in the kidney create a unique metabolic environment, accumulating glutathione to counter oxidative stress. Blocking this process prevents TLS formation or causes existing structures to shrink. Urine glutathione levels can serve as a non-invasive biomarker for TLSs and disease progression.

SourceInstitute for the Advanced Study of Human Biology (ASHBi), Kyoto University·JournalJournal of the American Society of Nephrology·TypeExperimental study·DateAug 26, 2025

Chinese Medical Journal study reports on the sex disparity and global temporal trends in the disease burden of urolithiasis

A study analyzing Global Burden of Diseases data from 204 countries and territories found a rising global incidence of urolithiasis over the past three decades, with notable sex disparities. The disease burden is highest in males, particularly in Southeast Asia, whereas females show a higher vulnerability to the increase in risk factors.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeData/statistical analysis·DateAug 18, 2025

Nature study: Estrogen protects the kidneys – research from Dresden and Heidelberg proves the relevance of gender-specific medicine for understanding disease and therapy

Research from Dresden and Heidelberg demonstrates that estrogen protects the kidneys against ferroptosis, a major cause of acute kidney damage. Estradiol increases resistance to ferroptosis by intercepting harmful radicals and activating a genetic program to prevent damage.

Predicting kidney disease trajectories with a simple blood test

Researchers developed a serum proteomics-based prediction model to identify biomarkers involved in ADPKD progression. The study identified 29 proteins linked to immune system, fat transport, and metabolism, which can predict kidney function decline rate. This breakthrough could lead to more accurate and earlier diagnosis of ADPKD.

SourceUniversity of Cologne·JournalNature Communications·TypeExperimental study·DateJul 21, 2025

Uncovering the relationship between oral function and lifestyle-related diseases

A recent study published by Fujita Health University found that poor oral health can increase the risk of lifestyle-related diseases such as diabetes and heart disease. The researchers examined 118 individuals aged 50 or above and found significant links between oral function test results and blood test results.

SourceFujita Health University·JournalJournal of Oral Rehabilitation·TypeData/statistical analysis·DateJul 10, 2025

New study by Korea University researchers reveals a safer alternative for long-term hepatitis B treatment

A new study by Korea University researchers reveals that switching to besifovir may improve patient kidney and bone health for long-term hepatitis B treatment. The study showed that patients who switched to besifovir had higher estimated glomerular filtration rate indicating improved kidney function and higher hip and spine bone densit...

SourceKorea University College of Medicine·JournalClinical and Molecular Hepatology·TypeRandomized controlled/clinical trial·DateMar 24, 2025

Potential treatment for chronic kidney disease in dogs revealed

A new study suggests that paricalcitol may help manage chronic kidney disease (CKD) in dogs by reducing renal secondary hyperparathyroidism and proteinuria. The treatment showed promise in stabilizing proteinuria, but raised questions about potential long-term effects on CKD progression.

SourceThe Hebrew University of Jerusalem·JournalJournal of Veterinary Internal Medicine·TypeRandomized controlled/clinical trial·DateMar 20, 2025

A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes

A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateFeb 14, 2025